The impact of serum anti-Müllerian hormone levels on preeclampsia prediction: a case control study

Objective: The aim of our study is to investigate serum antiMüllerian hormone (AMH) levels in patients who developed preeclampsia at the third trimester. Methods: Our study was conducted as a prospective case control study. The patients who were diagnosed with preeclampsia over 34 weeks of gestation were included in the study. Healthy pregnant women at the same weeks of gestation were included in the control group. The demographic characteristics, clinical and laboratory parameters, gestational outcomes and serum AMH values of the patients were compared. Results: A total of 62 pregnant women (32 preeclamptic and 30 control cases) were included in our study. The demographic data were similar in two groups. Systolic blood pressure, diastolic blood pressure, uric acid value and Esbach value were found to be significantly higher in the preeclampsia group. Serum AMH values were 0.79±0.40 ng/ml in the preeclampsia group and 1.45±0.93 ng/ml in the control group (p=0.01). There was a negative correlation between serum AMH values and the systolic blood pressure (r=-0.292, p=0.02). Conclusion: Serum AMH values are lower in the preeclamptic pregnant women at the third trimester compared to normotensive pregnant women.